AustralianSuper Backs Vantage Data Centers with €1.5 Billion Investment and Joins DigitalBridge as Key Shareholder
MELBOURNE, Australia & BOCA RATON, Fla. & DENVER–(BUSINESS WIRE)–AustralianSuper, Australia’s largest pension fund, today announced…
Month: September 2023
Accenture Invests in Open Cosmos to Expand Access to Satellite Data
PARIS–(BUSINESS WIRE)–At this year’s World Satellite Business Week in Paris, Accenture (NYSE:ACN) announced an investment…
World title for TOYOTA GAZOO Racing after Fuji win
Toyota City, Japan, Sep 11, 2023 – (JCN Newswire) – TOYOTA GAZOO Racing earned a…
RDARS Announces Non-Brokered Debenture Financing
Toronto, Ontario–(Newsfile Corp. – September 10, 2023) – RDARS Inc. (CSE: RDRS) (OTCQB: RDRSF) (“RDARS”…
One-two for TOYOTA GAZOO Racing’s title protagonists in Greek epic
Toyota City, Japan, Sep 11, 2023 – (JCN Newswire) – TOYOTA GAZOO Racing World Rally…
Q&M Dental Group Sets the Gold Standard for Best Investor Relations at Singapore Corporate Awards
SINGAPORE, Sep 11, 2023 – (ACN Newswire) – Q&M Dental Group Limited is honoured to…
Crypto Presale: Crypto’s Go-to Multimedia Platform for News, Insights, and Education
DUBAI, Sep 11, 2023 – (ACN Newswire) – Web3 multimedia outlet Crypto Presale announces its…
SolarWinds to Participate in Gartner IT Symposium/Xpo 2023 Worldwide Events
SolarWinds will showcase its product portfolio and speak on how integrated observability and service management…
Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-1 Study Evaluating Treatment of Patients with Acromegaly
83% of Participants on Paltusotine Maintained IGF-1 ≤1.0 xULN vs. 4% on placebo (p<0.0001) Mean…
Mineralys Therapeutics Announces JAMA Publication of Full Target-HTN Phase 2 Trial Results for Lorundrostat in Uncontrolled and Treatment-Resistant Hypertension
– Lorundrostat, a highly selective aldosterone synthase inhibitor, demonstrated robust, double-digit reduction in systolic blood…
Mineralys Therapeutics Presents Target-HTN Phase 2 Trial Results in Late-Breaking Science Session at 2023 AHA Hypertension Scientific Sessions
– Lorundrostat, a highly selective aldosterone synthase inhibitor, demonstrated robust, double-digit reduction in systolic blood…
Supernus Announces New Qelbree® Data Showing Improvement in ADHD Symptoms
Topline results from Phase IV study demonstrate Qelbree is safe and well-tolerated, and significantly improved…
Hong Kong Watch & Clock Fair, Salon de TE attract nearly 15,000 buyers
HONG KONG, Sep 10, 2023 – (ACN Newswire) – The physical exhibitions of the 42nd…
Hargroves Helping Hand Media-Group Launches Marketing Services For Life Coaches
Hargroves Helping Hand Media-Group announces omnichannel marketing strategies for qualifying businesses to help them gain…
Leading Capital Markets Advisory ARX Sponsors Israel’s 2023 Investor Conference
TEL AVIV, Israel–(BUSINESS WIRE)–ARX Advisory LTD, a leading data-backed capital markets advisory, proudly announces its…
VanEck Announces Changes to ETF Product Line
NEW YORK–(BUSINESS WIRE)–VanEck announced today that it plans to close and liquidate one of its…